Trial Profile
A Phase IIIb, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in Hospitalized Adults (TANGO III)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Meropenem/vaborbactam (Primary) ; Piperacillin/tazobactam
- Indications Nosocomial pneumonia
- Focus Therapeutic Use
- Acronyms TANGOIII
- Sponsors Melinta Therapeutics; The Medicines Company
- 09 Jan 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Jan 2017 New trial record